Table 3.
Interactive effects of GM 5/21, GM 3/17, KM 1/3, FcγRIIa R/H, FcγRIIIa F/V genotypes on anti-MUC1 IgG antibody levels (AU/μL) in healthy controls.
| Loci | Genotype combination | N | Mean ± SE | P-value |
|---|---|---|---|---|
| Whites | ||||
| GM 5/21 x FcγRIIa | (5/5); (H/R, R/R) | 92 | 5.25 ± 1.05 | 0.032 |
| (5/5); (H/H) | 34 | 5.87 ± 1.09 | ||
| (5/21, 21/21); (H/R, R/R) | 101 | 5.24 ± 1.05 | ||
| (5/21, 21/21); (H/H) | 33 | 4.34 ± 1.09 | ||
| GM 3/17 x KM 1/3 | (3/17, 3/3); (KM 1/1) | 5 | 7.16 ± 1.24 | 0.029 |
| (3/17, 3/3); (KM 1/3) | 46 | 4.93 ± 1.07 | ||
| (3/17, 3/3); (KM 3/3) | 137 | 5.07 ± 1.04 | ||
| (17/17); (KM 1/1) | 2 | 5.40 ± 1.40 | ||
| (17/17); (KM 1/3) | 17 | 7.31 ± 1.12 | ||
| (17/17); (KM 3/3) | 54 | 5.07 ± 1.07 | ||
| Japanese (Nagano) | ||||
| GM 3/17 x KM 1/3 | (3/17, 17/17); (KM 3/3) | 190 | 5.25 ± 1.03 | 0.032 |
| (3/17, 17/17); (KM 1/1, KM | 204 | 5.19 ± 1.03 | ||
| 1/3) | ||||
| (17/17); (KM 3/3) | 1 | 2.40 | ||
| (17/17); (KM 1/1, KM 1/3) | 2 | 6.08 ± 1.29 | ||
| GM 3/17 x FcγRIIIa | (3/17, 17/17); (F/F) | 220 | 5.23 ± 1.02 | 0.029 |
| (3/17, 17/17); (F/V) | 142 | 5.25 ± 1.03 | ||
| (3/17, 17/17); (V/V) | 23 | 4.87 ± 1.08 | ||
| (17/17); (F/F) | 1 | 8.40 | ||
| (17/17); (F/V) | 2 | 3.25 ± 1.28 | ||
| (17/17); (V/V) | 0 | NA | ||